

**EXHIBIT L**

**TO TANNER DECLARATION**

1 **WILSON SONSINI GOODRICH & ROSATI P.C.**  
 2 PAUL D. TRIPODI II (SBN 162380)  
 3 [ptripodi@wsgr.com](mailto:ptripodi@wsgr.com)  
 4 WENDY L. DEVINE (SBN 246337)  
 5 [wdevine@wsgr.com](mailto:wdevine@wsgr.com)  
 6 NATALIE J. MORGAN (SBN 211143)  
 7 [nmorgan@wsgr.com](mailto:nmorgan@wsgr.com)  
 8 633 West Fifth Street, Suite 1550  
 9 Los Angeles, CA 90071  
 10 Telephone: 323-210-2900  
 11 Fax: 866-974-7329

7 **Hilgers Graben PLLC**  
 8 MICHAEL T. HILGERS (*Pro Hac Vice*)  
 9 [mhilgers@hilgersgraben.com](mailto:mhilgers@hilgersgraben.com)  
 10 575 Fallbrook Blvd, Suite 202  
 11 Lincoln, NE 68521  
 12 Telephone: 402-218-2106  
 13 Fax: 402-413-1880

14 *Attorneys for Plaintiff NuVasive, Inc.*

15 UNITED STATES DISTRICT COURT  
 16 SOUTHERN DISTRICT OF CALIFORNIA – SAN DIEGO DIVISION

17 NUVASIVE, INC., a Delaware  
 18 corporation,

19 Plaintiff,

20 v.

21 ALPHATEC HOLDINGS, INC., a  
 22 Delaware corporation, and ALPHATEC  
 23 SPINE, INC., a California corporation,

24 Defendants.

Case No. 18-cv-00347-CAB-MDD

**PLAINTIFF NUVASIVE, INC.’S  
 FOURTH SUPPLEMENTAL  
 RESPONSES TO DEFENDANTS’  
 INTERROGATORY NOS. 3 AND  
 13 (IMPLANT PATENT PHASE)**

**Judge:** Cathy A. Bencivengo

28

1 burdensome, and inconsistent with and/or seek to impose upon NuVasive  
2 obligations beyond those required by the Federal Rules of Civil Procedure.

3 24. NuVasive objects to the definition of the terms “concerning” or  
4 “concern” as being overly broad, unduly burdensome, vague, ambiguous, and not  
5 proportional to the needs of this case. In particular, these terms are defined as  
6 “relating to, referring to,” which are terms included in the previous definition.  
7 NuVasive believes that including a previously defined term as the definition for a  
8 different term makes the definition overly broad.

9 25. NuVasive objects to the term “identify” as being overly broad and  
10 unduly burdensome in that it seeks to impose obligations beyond those imposed by  
11 the Federal Rules of Civil Procedure, because it necessarily results in compound  
12 interrogatories that, when counted according to their discrete subparts, exceed the  
13 number of interrogatories allowed by the Federal Rules. NuVasive will only  
14 provide responses to 25 interrogatories, counting separately all discrete subparts.  
15 By answering the following Interrogatories, NuVasive does not consent in any way  
16 to answering more than the 25 interrogatories, counting separately all discrete  
17 subparts, nor does it waive its objection to the number of discrete subparts  
18 contained within the present Interrogatories. Should Defendant seek further  
19 response to the below Interrogatories, NuVasive reserves its right to object on the  
20 basis that the present Interrogatories already contain well-over 25 discrete subparts.

21 **SUPPLEMENTAL RESPONSES TO INTERROGATORIES**

22 **INTERROGATORY NO. 3:**

23 For each asserted claim of the patents-in-suit, describe in detail the facts and  
24 circumstances relating to the first written description, offer for sale, sale, public  
25 disclosure, public use, or disclosure to any person other than a named inventor of  
26 the claimed invention, including, without limitation, the identities of the persons  
27 involved in each such event, the identities of the persons most knowledgeable  
28 regarding each such event, the date on which each such event occurred, and the

1 identification of each document that reflects or relates to such facts and  
2 circumstances.

3 **RESPONSE TO INTERROGATORY NO. 3:**

4 NuVasive incorporates by reference each of the General Objections.  
5 NuVasive objects to this interrogatory on the grounds that it contains at least three  
6 discrete subparts, is compound, and constitutes at least three interrogatories.  
7 NuVasive objects to this interrogatory as vague and ambiguous with respect to the  
8 term “the circumstances.” NuVasive objects to this interrogatory on the grounds  
9 and to the extent it is overly broad, unduly burdensome, not proportional to the  
10 needs of the case, and not relevant to any claim or defense in this case.

11 Specifically, NuVasive objects to the interrogatory to the extent it calls for  
12 NuVasive to “describe in detail” the circumstances relating to the first descriptions,  
13 disclosures and sales of the claimed inventions. NuVasive objects to this  
14 interrogatory to the extent it seeks “Privileged Information.” NuVasive objects to  
15 this interrogatory to the extent it calls for legal conclusions. NuVasive objects to  
16 this interrogatory to the extent it attempts the shift the burden of proof regarding  
17 invalidity to NuVasive. NuVasive objects to this interrogatory to the extent it seeks  
18 information no longer in NuVasive’s possession, custody, or control.

19 Subject to and without waiving the foregoing objections, NuVasive responds  
20 as follows: the first written description for each of the patents-in-suit is at least as  
21 early as the earliest priority date of the respective patent-in-suit based on the  
22 earliest filed parent patent application.

23 Additionally, Alphatec has admitted that NuVasive’s “eXtreme Lateral  
24 Interbody Fusion” product (or “XLIF”), which includes the MaXcess access  
25 system and CoRoent XL implants, embodies the asserted claims of the patents-in-  
26 suit. Doc. No. 48 at 16. Based on information available to NuVasive at this time,  
27 NuVasive states that it launched aspects of XLIF in October 2003 at the North  
28 American Spine Society (NASS) Annual Meeting, including its MaXcess access

1 system, and specifically MaXcess I. Persons involved in this this launch include  
2 Pat Miles, Eric Finley, and Scot Martinelli. In addition, MaXcess III launched on  
3 September 12, 2006, and MaXcess III Solid launched on November 13, 2008.

4 In October 2004, at NASS, NuVasive launched the CoRoent XL implant as  
5 part of XLIF. The persons involved in the launch of CoRoent XL are Matthew  
6 Curran, Matthew Copp, Scot Martinelli, Patrick Miles, and David Ivanko.

7 In addition, pursuant to Local Patent Rule 3.2(b) and Fed. R. Civ. P. 33(d),  
8 NuVasive further states that it will produce and has produced non-privileged  
9 documents from which the information requested can be ascertained, including  
10 documents bearing the following Bates numbers:

11 NUVA\_ATEC0000001 – NUVA\_ATEC0000290;

12 NUVA\_ATEC0000544 – NUVA\_ATEC0014446;

13 NUVA\_ATEC0014504 – NUVA\_ATEC0015487;

14 NUVA\_ATEC0016164 – NUVA\_ATEC0016948;

15 NUVA\_ATEC0016949 – NUVA\_ATEC0039458;

16 NUVA\_ATEC0039459 – NUVA\_ATEC0040421;

17 Discovery is ongoing and NuVasive reserves its right to amend or  
18 supplement its response to this interrogatory.

19 **SUPPLEMENTAL RESPONSE TO INTERROGATORY NO. 3:**

20 In addition to its previously asserted General and Specific Objections,  
21 NuVasive continues to object that this interrogatory is overly broad, unduly  
22 burdensome, and not proportional to the needs of the case because it seeks a  
23 “detailed” description of information spanning nearly two decades that is no longer  
24 readily accessible to NuVasive due to the passage of time and relevant personnel  
25 departing the company over the intervening 15-plus years. In light of this,  
26 NuVasive maintains that its previous response and citation to documents pursuant  
27 to Fed. R. Civ. P. 33(d) is proper at least because the burden of deriving the  
28

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.